Kristina Burow has a well-trained eye. That’s true of her work at ARCH Venture Partners, one of the drug industry’s largest and most active investment firms, and also outside of work — those who know her say Burow is a deadly shot with a pistol.
Burow is a managing director at ARCH, where she has been influential in building bold and well-capitalized startups. Some of her latest are the genetic medicines startup Orbital Therapeutics and Neumora Therapeutics, which is part of a small group of startups hoping to make strides in treating psychiatric diseases. Neumora was one of the few biotechs to go public through an IPO last year. Burow also sits on the boards of several emerging biotech companies, helping to steer how they stress-test their science and what types of therapies to pursue.
Her role behind the scenes in biotech earned her a spot on the third annual STATUS List, which recognizes leaders in health, medicine, and science. STAT spoke with Burow about what’s getting her fired up in the health care industry and how she’d change the dynamics between the drug companies and government.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect